上海医药集团股份有限公司关于与贵州生诺生物科技有限公司合作协议终止的公告

Group 1 - The core point of the announcement is the termination of the cooperation agreement between Shanghai Pharmaceuticals and Guizhou Shengnuo Biotech, which was based on mutual agreement and does not impose additional obligations on Shanghai Pharmaceuticals [3][4]. - The original cooperation agreement was signed on October 8, 2021, granting Shanghai Pharmaceuticals exclusive rights for the production and industrial sales of the new acid suppressant X842 in China [2]. - The termination agreement stipulates that Shanghai Pharmaceuticals will receive a refund of 110 million yuan within 45 working days after the agreement is signed, along with interest at an annual rate of 3% [3]. Group 2 - Shanghai Pharmaceuticals' subsidiary, Shenyang Dongying, has received approval from the National Medical Products Administration for the production of Minoxidil solution, which is classified as a Class 3 chemical drug [7][8]. - The Minoxidil solution is available in two specifications: 2% and 5%, with the 2% formulation used for treating male pattern baldness and alopecia, while the 5% formulation is restricted to male use [9]. - The market for Minoxidil topical formulations in China was valued at approximately 236 million yuan in 2024, indicating a significant market opportunity for the newly approved product [10].